• Regulatory NewsRegulatory News

    The Next Emflaza: Acer Therapeutics Looks to Take a Page Out of Marathon's Book

    Last year, Marathon Pharmaceuticals took an inexpensive steroid available for sale in the EU and Canada and brought it through the US Food and Drug Administration's (FDA) approval process before trumpeting an $89,000 annual price. The move, criticized by lawmakers and others and then the company was bought by PTC Therapeutics, offered a test case for how a company can use FDA's approval system and the US pricing system to reap outsized rewards without doing any ...
  • Regulatory NewsRegulatory News

    Senators Ask GAO to Probe Orphan Drug Act as Questions Pile up Over Marathon’s Pricey Steroid

    As US Duchenne Muscular Dystrophy (DMD) patients may be hit with a 50 to 70 times more expensive price for a steroid they have been importing from the EU and Canada for about $1,000 per year, eight Democratic senators sent a letter on Friday to Marathon Pharmaceuticals questioning the orphan drug Emflaza’s (deflazacort) $89,000 list price, while three Republican senators on Friday also asked the US Government Accountability Office (GAO) to look into orphan drugs in ge...
  • Regulatory NewsRegulatory News

    Sanders, Cummings Slam Marathon’s $89,000 Price Tag for Old Steroid

    Sen. Bernie Sanders (D-VT) and Rep. Elijah Cummings (D-MD) on Monday wrote to Illinois-based Marathon Pharmaceuticals CEO Jeffrey Aronin, calling the company’s plan to charge $89,000 annually for its recently approved treatment “outrageous.” Not only did Marathon not develop the steroid, known as Emflaza (Deflazacort) and approved by the US Food and Drug Administration last week to treat Duchenne Muscular Dystrophy, but the letter notes that the steroid is curren...